Immuron Q4 2026 Earnings Report

Immuron EPS Results

• Actual EPS: -$0.08
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Immuron Revenue Results

• Actual Revenue: $1.27 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Immuron Announcement Details

• Quarter: Q4 2026
• Date: 8/14/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Immuron (NASDAQ:IMRN) Limited (NASDAQ: IMRN) is a biopharmaceutical company focused on developing and commercializing orally delivered therapeutics based on highly specific antibodies derived from hyperimmune bovine colostrum. Its approach is designed to target pathogens and disease-related factors within the gastrointestinal tract without requiring systemic absorption.

The company’s leading commercial product is Travelan, an oral antibody-based product intended to help prevent travelers’ diarrhea caused by enterotoxigenic Escherichia coli (ETEC). Travelan is marketed in the United States and Australia, where it is available under applicable regulatory approvals and labeling. Immuron has also investigated additional applications for its antibody platform, including candidates aimed at gastrointestinal infections and inflammatory or metabolic disorders.

Immuron is headquartered in Melbourne, Australia, and has historically conducted research, clinical development and commercialization activities in Australia and the United States. Its development programs have included IMM-124E and IMM-529, which have been studied for potential uses in conditions such as nonalcoholic steatohepatitis and Clostridioides difficile infection. The company’s activities and leadership may change as its clinical and commercial programs develop.